No longer trading

Acquired by XOMA Royalty Corporation

The acquisition closed on February 9, 2026 (SEC 8-K 2.01). Its last closing price was on February 6, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. Source: SEC 8-K 2.01

GBIO

Generation Bio Co. GBIO

NasdaqSmall CapHealthcare

Final 13F Pro quality score

Final rank #2,631 of 2,856 · as of July 1, 2026

Why it scores 23Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.59M

Quarter to Sep 30

Net income

$-5.52M

Quarter to Sep 30

Free cash flow

$-52.68M

Quarter to Sep 30

Top Institutional Holders

as of Q2 2026
HUNTINGTON NATIONAL BANK
$00.0%
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q3 2025
EDGAR

Net Income

Q3 2025
EDGAR

EPS (Diluted)

Q3 2025
EDGAR

ROIC

Q3 2025
EDGAR

Free Cash Flow

Q3 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/GBIO

Earnings Per Share

13fpro.ai/company/GBIO

Loading ratio trend…

GBIO key financials by period

Reported revenue, net income and operating margin by fiscal year, from Generation Bio Co.'s annual filings on SEC EDGAR.

Generation Bio Co. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$19.9M$-131.7M—
FY 2023$5.9M$-126.6M—
Source: GBIO filings on SEC EDGAR →

GBIO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Generation Bio Co. (GBIO): stock profile, AI score and financials

Acquired by XOMA Royalty Corporation: Generation Bio Co. (GBIO) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on February 9, 2026 (SEC 8-K 2.01). Its last closing price was on February 6, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from July 1, 2026. Generation Bio Co. (GBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks GBIO using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q3 2025), Generation Bio Co. reports quarterly revenue of $1.6M, net income of $-5.5M, free cash flow of $-52.7M. GBIO trades on the Nasdaq exchange and files with the SEC under CIK 1733294. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Generation Bio Co. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1733294 →